Investigational drug · Phase 3
Olpasiran
Also called: AMG 890
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiovascular Disease, Atherosclerotic Cardiovascular Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "Olpasiran"
First trial start
2022
Dec 14, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olpasiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cardiovascular Disease
- Atherosclerotic Cardiovascular Disease
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Olpasiran" as an intervention, largest first.
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular EventsPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07136012 · 11,000 participants (planned) · Start Aug 22, 2025 · Primary completion Oct 20, 2031
Drug: Olpasiran; Placebo · For: Cardiovascular Disease
Sites: Alexander City, Alabama; Birmingham, Alabama; Daphne, Alabama · 261 sites in all
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes TrialPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT05581303 · 7,297 participants · Start Dec 14, 2022 · Primary completion Mar 31, 2028
Drug: Placebo; Olpasiran · For: Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 492 sites in all
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07293260 · 406 participants (planned) · Start Mar 23, 2026 · Primary completion Jun 15, 2028
Drug: Olpasiran; Placebo · For: Cardiovascular Disease
Sites: Bridgeport, Connecticut; Jacksonville, Florida; Overland Park, Kansas · 40 sites in all
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding StudyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT04270760 · 281 participants · Start Jul 28, 2020 · Primary completion Dec 27, 2021
Drug: Olpasiran; Placebo · For: Cardiovascular Disease
Sites: Beverly Hills, California; Boca Raton, Florida; Atlanta, Georgia · 36 sites in all
AmgenAmgen (AMGN)
NCT05489614 · 33 participants · Start Sep 13, 2022 · Primary completion Oct 24, 2023
Drug: Olpasiran · For: Renal Impairment
Sites: Rialto, California; Yucaipa, California; Miami, Florida · 6 sites in all
AmgenAmgen (AMGN)
NCT06411860 · 32 participants · Start Sep 12, 2024 · Primary completion Nov 29, 2024
Drug: Olpasiran; Moxifloxacin · For: Basic Science
Sites: Leeds, United Kingdom
AmgenAmgen (AMGN)
NCT05481411 · 25 participants · Start Sep 13, 2022 · Primary completion Apr 5, 2023
Drug: Olpasiran · For: Hepatic Impairment
Sites: Rialto, California; Orlando, Florida; San Antonio, Texas
AmgenAmgen (AMGN)
NCT04987320 · 24 participants · Start Jul 28, 2021 · Primary completion Nov 12, 2021
Drug: Olpasiran · For: Elevated Serum Lipoprotein(a)
Sites: Hong Kong, Hong Kong
- Olpasiran Expanded Access ProgramAvailable
AmgenAmgen (AMGN)
NCT07079267
Drug: Olpasiran
Newest research
PubMed records naming it or its code names, newest first.
- RNA-Targeted Therapeutics in Cardiovascular Risk Reduction: From Gene Silencing to Precision Cardiology.
Karim A, Binte Imran S, Yousuf YM, et al. · Cardiol Rev 2026
- Nucleic acid-based and small-molecule therapies for lipoprotein(a) lowering: what the trials teach us and what they do not.
Yamaji T, Barkas F, Ray KK · Expert Opin Emerg Drugs 2026
- Pelacarsen and Lp(a)HORIZON: Interpreting the disconnect between lipoprotein(a) lowering and cardiovascular outcomes.
Sabouret P, Giamundo DM, Asher E, et al. · Am J Med 2026
- RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms.
Parcha V, Bittner VA · Curr Atheroscler Rep 2026
- Novel pharmacological targets for the treatment of aortic stenosis.
Anchouche K, Small AM, Thanassoulis G · Eur Heart J Valvular Struct Heart Dis 2026
- Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications.
Acierno C, D'Ardes D, Boccatonda A, et al. · J Cardiovasc Pharmacol 2026
Also in development for Cardiovascular Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- AZD0780Phase 36 trials
AstraZeneca · Cardiovascular Disease, Dyslipidaemia, Heterozygous Familial Hypercholesterolaemia
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- Adjuvanted RSVPreF3 vaccinePhase 22 trials
GSK · Cardiovascular Disease, Respiratory Syncytial Virus Infections
- VERVE-102LY4636581Phase 21 trial
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.